EDETATE CALCIUM DISODIUM

Post-LOE

edetate calcium disodium

R-Pharm US

ANDAINJECTIONINJECTABLE

Approved

May 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

EDETATE CALCIUM DISODIUM (edetate calcium disodium) by R-Pharm US is clinical pharmacology the pharmacologic effects of edetate calcium disodium are due to the formation of chelates with divalent and trivalent metals. Approved for blood levels, depot stores of lead in lead poisoning (acute, chronic) and 2 more indications. First approved in 2023.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY The pharmacologic effects of edetate calcium disodium are due to the formation of chelates with divalent and trivalent metals. A stable chelate will form with any metal that has the ability to displace calcium from the molecule, a feature shared by lead, zinc, cadmium,…

Indications (5)

Worked on EDETATE CALCIUM DISODIUM at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.